GLP-1/GIP Dual Bias: Evolution Of Long-acting Formulations

On February 16, 2026, Shiyao Group announced that its GLP-1/GIP receptor dual directional agonist peptide long-acting injection (SYH2082 injection) has been approved by the US Food and Drug Administration (FDA) for clinical trials in the United States. SYH2082 is expected to become a long-acting GLP-1/GIP receptor dual biased agonist with leading potential in clinical development, administered once a month. Relying on our group's long-acting formulation technology platform, SYH2082 achieves monthly administration, improving patient compliance and medication convenience.

SYH2082 can selectively activate the cAMP pathway, reduce B-arfestin recruitment, thereby reducing receptor endocytosis and desensitization, enhancing drug efficacy and prolonging the duration of action. Meanwhile, SYH2082 combines the long half-life modification platform technology and the long-acting formulation platform technology to achieve sustained weight loss within the dosing interval. In preclinical studies, SVH2082 has shown superior efficacy in long-term weight loss and maintenance compared to similar marketed products, and supports a monthly medication regimen. In toxicology studies, SYH2082 has good tolerability and no significant adverse reactions have been observed.

Semaglutide Powder CAS 910463-68-2

1.We supply
(1)Tablet
(2)Gummies
(3)Capsule
(4)Spray
(5)API(Pure powder)
(6)Pill press machine
https://www.achievechem.com/pill-press
2.Customization:
We will negotiate individually, OEM/ODM, No brand, for secience researching only.
Internal Code: BM-2-4-008
Semaglutide CAS 910463-68-2
Analysis: HPLC, LC-MS, HNMR
Technology support: R&D Dept.-4

We provide Semaglutide Powder, please refer to the following website for detailed specifications and product information.

Product:https://www.bloomtechz.com/synthetic-chemical/peptide/semaglutide-powder-cas-910463-68-2.html

On February 17, 2026, Novo Nordisk announced that its marketing application for 7.2mg semaglutide for weight management had been approved by the European Medicines Agency (EMA).

This approval is based on the positive results of the Phase II STEP UP study and the Phase III STEP UPT2D study.
The STEPUP study results showed that in obese adult patients without diabetes, after 72 weeks of treatment, the weight loss effect of the 7.2mg smeglutide group was significantly better than that of the placebo group, with a statistically significant difference. The baseline average weight of the subjects was 113kg.

According to the completed treatment analysis, the weight loss in the 7.2mg, 2.4mg semaglutide groups and placebo group was 20.7%, 6%, 17.5%, and 2.4%, respectively. Among them, 33.2% of patients in the 7.2mg group lost more than 25% weight, 16.7% in the 2.4mg group, and 0.0% in the placebo group; The intention to treat analysis results showed that the weight loss of the three groups was 18.7%, 15.6%, and 3.9%, respectively.
In terms of safety, 7.2mg semaglutide showed good safety and tolerability in this study. The most common adverse events are gastrointestinal adverse events, the vast majority of which are mild to moderate and decrease over time, consistent with the characteristics of GLP-1 receptor agonists in previous studies.

On February 18, 2026, Huadong Pharmaceutical's GLP-1R/GIPR agonist HDM1005 launched its first head to head phase I clinical trial.

The phase study launched this time is a multicenter, randomized, open label, positive drug controlled clinical trial (=912), which aims to evaluate the efficacy and safety of HDM1005 (subcutaneous injection, once a week) versus Masidotide (subcutaneous injection, once a week) in treating type 2 diabetes patients who still have poor blood glucose control after treatment with metformin alone or combined with SGLT2 inhibitor. The main endpoint of the study is the change in glycated hemoglobin (HbAlc) levels from baseline.

HDM1005 (poterepatide) is a peptide based human GLP-1R/GIPR dual target long-acting agonist developed by Huadong Pharmaceutical's subsidiary, Zhongmei Huadong. Preclinical studies have shown that HDM1005 can activate GLP-IR and GIPR, promote the production of cyclic adenosine monophosphate (CAMP), increase pancreatic cord secretion, suppress appetite, delay gastric emptying, improve metabolic function, thereby improving plasma volume, reducing oxidative stress and systemic inflammation, and enhancing cardiovascular adaptability; It has the effects of lowering blood sugar, reducing weight, improving MASH, and preserving ejection fraction in heart failure (HFpEF). Meanwhile, existing data shows that HDM1005 has significant weight loss efficacy, good safety and tolerability.